Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.